We recently read with great interest the report by Lacunza-Ruiz et al. (1) describing the management of a coronary embolism (CE) as a complication of prosthetic mitral valve thrombosis. We thank the authors for their report that included a rare complication of prosthetic valve thrombosis.
However, we have some essential criticisms regarding some major drawbacks in the management of the patient. CE is a rare cause of acute coronary syndrome (ACS) in patients with prosthetic heart valves. The majority of patients with a prosthetic heart valve who present with ACS have non-ST-segment elevation ACS rather than ST-segment elevation ACS (2).
The information in the literature about this complication is scarce and mainly based on case reports.
There is a controversy regarding the treatment of patients with CE. In the current literature, thrombolytic therapy (TT), stent implantation, and embolectomy were performed as reperfusion strategies, but there is no consensus regarding the optimal treatment. As a result, we can conclude that CAG can be deferred until after TEE to decide the best treatment strategy for PVT patients who present with CE. TT should be considered as an initial treatment modality in these patients.
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